Tripeptide Collagen and GLP-1: What the Milan Research Found
In short
Many people are now taking GLP-1 medications such as Ozempic and Mounjaro, and plenty are asking the same quiet question: is there anything food-based that works with the body's own GLP-1 system rather than against it? University of Milan researchers have looked at exactly that for FoYL's tripeptide collagen. Here is what they found, in plain English, and what it does not mean.
First, the context. GLP-1 is a hormone your gut releases after you eat. It helps signal fullness and helps the body manage blood sugar after a meal. GLP-1 medications are prescription drugs that act on the same system. This post is not about those drugs, and nothing here replaces or changes a prescription. It is about a food ingredient and what laboratory testing showed about how it behaves around the same signalling pathway.
Two moving parts: GLP-1 and the enzyme that clears it
Two things decide how much GLP-1 signalling you get after a meal. Specialised cells in the gut release the hormone. Then an enzyme called DPP-IV breaks it down within minutes. More release, or slower breakdown, means the signal lasts longer.
What the University of Milan analysis found
The tripeptide collagen was independently analysed by the University of Milan, Department of Pharmaceutical Sciences, using laboratory models. FoYL's tripeptide sits at 300 to 500 Daltons with more than 80% in true tripeptide form, compared with around 2,000 Daltons for conventional collagen. In those models:
- GLP-1 release rose by about 17% in gut hormone-producing cells (STC-1) exposed to the tripeptide, compared with the control.
- DPP-IV, the enzyme that breaks GLP-1 down, was inhibited by 30 to 47% in enzyme tests at roughly 2 to 5 grams per serve.
- The effect held in human intestinal cells (Caco-2). The tripeptide reduced DPP-IV activity there. Ordinary collagen peptides showed no significant effect under the same conditions.
- Cell safety was high: at least 95% of cells remained viable.
Put simply: in the laboratory, the tripeptide showed signs of supporting GLP-1 signalling at both ends, helping release it and slowing its clearance.
This is tripeptide collagen, not ordinary collagen
These results are for FoYL's tripeptide collagen: peptides of 300 to 500 Daltons, more than 80% in true tripeptide form. Ordinary collagen peptides are a different material at around 2,000 Daltons, and in the human intestinal cell test they showed no significant effect. Please do not read these findings across to collagen in general.
The honest version
These are laboratory findings in cells and enzymes, not a human clinical trial. FoYL Tripeptide Collagen is a food, not a medicine. It does not replace, boost or change any medication, and it is not a weight-loss product. If you take a GLP-1 medication, talk to your prescriber or dietitian before changing what you take.
Why the size of the molecule matters here
The Milan work compared the tripeptide against conventional collagen, and the difference came down to peptide size and make-up. Smaller, more uniform peptides present a different set of building blocks to the gut than a large, mixed hydrolysate does. That is why this post is about tripeptide collagen specifically, and not about collagen in general. It is the same structural idea explained in our post on Daltons, now seen from the gut-signalling side.
A note on muscle if you are on a GLP-1 medication
Large trials of semaglutide have shown that weight lost on these drugs includes some lean mass as well as fat. In the main trial's body-composition substudy, total lean mass fell 9.7% and fat mass fell 19.3% over 68 weeks (Wilding et al., 2021). That is why dietitians so often talk about protein and resistance training for people on these medications. Collagen is not a complete protein and is not a substitute for either, which we explain in Is Collagen a Complete Protein?
Common questions
Can I take tripeptide collagen while on Ozempic or Mounjaro? It is a single-ingredient food, but your prescriber or dietitian knows your situation, so ask them first.
Does this mean it works like a GLP-1 medication? No. Medications are tested for specific medical outcomes in people. The Milan work is cell and enzyme modelling of a food ingredient.
What dose was tested? The enzyme tests used roughly 2 to 5 grams per serve. FoYL's standard daily dose is 2.5 grams.
Want the full picture of how the tripeptide was analysed? The science page lays out the method and the figures.
Independently analysed. Single ingredient. Easy to take every day.
P.S. Laboratory results tell you where to look, not what will happen in your body. We would rather say that plainly than sell you a leap.
